Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | TTR | P02766 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167885 | 1.00 | APP (1.00) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL13191839 | 1.00 | APP (1.00) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL29373798 | 1.00 | APP (1.00) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL16674442 | 0.94 | APP (0.88) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1603799 | 0.93 | APP (0.87) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1603801 | 0.93 | APP (0.87) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL19872782 | 0.90 | APP (0.82) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL1976945 | 0.88 | CYP1A2 (0.81) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL13191735 | 0.87 | APP (0.76) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL5360751 | 0.87 | APP (0.77) | APPMAPTCYP1A2NFE2L2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808155-B2 | Apparatus to detect amyloid in a patient user's retina in a diagnosis, advancement and prognosis of alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative disorders and ocular diseases | NEUROVISION IMAGING LLC (US) | 2017-11-07 | — | — | US | claimed |
| US-20140176908-A1 | APPARATUS AND METHOD FOR DETECTING AMYLOID IN A RETINA IN A DIAGNOSIS, ADVANCEMENT, AND PROGNOSING OF ALZHEIMER'S DISEASE, TRAUMATIC BRAIN INJURY, MACULAR DEGENERATION AND A PLURALITY OF NEURODEGENERATIVE DISSORDERS AND OCULAR DISEASES | WILDCAT PARTNER HOLDINGS, LP | 2014-06-26 | — | — | US | claimed |
| US-20210079075-A1 | NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSITY OF BONN (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20200339670-A1 | NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HENEKA MICHAEL (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3728312-A1 | NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Heneka, Michael (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200138351-A1 | Method for Measuring Fluorescence in Ocular Tissue | COGNOPTIX, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10350309-B2 | Methods of preparing ophthalmic formulations and uses of same | COGNOPTIX, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180126008-A1 | Methods Of Preparing Ophthalmic Formulations And Uses Of Same | COGNOPTIX, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9808155-B2 | Apparatus to detect amyloid in a patient user's retina in a diagnosis, advancement and prognosis of alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative disorders and ocular diseases | NEUROVISION IMAGING LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160278677-A1 | Method for Measuring Fluorescence in Ocular Tissue | COGNOPTIX, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9451909-B2 | System and method for detecting amyloid proteins | COGNOPTIX, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20140176908-A1 | APPARATUS AND METHOD FOR DETECTING AMYLOID IN A RETINA IN A DIAGNOSIS, ADVANCEMENT, AND PROGNOSING OF ALZHEIMER'S DISEASE, TRAUMATIC BRAIN INJURY, MACULAR DEGENERATION AND A PLURALITY OF NEURODEGENERATIVE DISSORDERS AND OCULAR DISEASES | WILDCAT PARTNER HOLDINGS, LP | 2014-06-26 | — | — | US | disclosed |
| US-20130135580-A1 | System and Method for Detecting Amyloid Proteins | COGNOPTIX, INC | 2013-05-30 | — | — | US | disclosed |
| US-20130114042-A1 | Ocular Imaging | COGNOPTIX, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8388134-B2 | Ocular imaging | COGNOPTIX, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110116041-A1 | Ocular Imaging | COGNOPTIX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110080559-A1 | Ocular Imaging | COGNOPTIX, INC. | 2011-04-07 | — | — | US | disclosed |
| US-7828436-B2 | Ocular imaging | NEUROPTIX CORPORATION (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080088795-A1 | Ocular imaging | COGNOPTIX, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20070224593-A1 | Diagnosis of transmissible spongiform encephalopathy | GOLDSTEIN LEE E | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350309-B2 | Methods of preparing ophthalmic formulations and uses of same | PDE6G, PDE6A, F12 | APP 977/4885MAPT 318/4885CYP1A1 1423/4885 |
| US-20200138351-A1 | Method for Measuring Fluorescence in Ocular Tissue | FUCA1, EYA3, ALDH1A2 | APP 3595/4885MAPT 2518/4885CYP1A1 4196/4885 |
| US-20160278677-A1 | Method for Measuring Fluorescence in Ocular Tissue | ALDH1A2, FUCA1, EYA3 | APP 2225/4885MAPT 2162/4885CYP1A1 3764/4885 |
| US-20180126008-A1 | Methods Of Preparing Ophthalmic Formulations And Uses Of Same | PDE6G, PDE6A, F12 | APP 977/4885MAPT 318/4885CYP1A1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.